OncoMark initiate testing of TransATAC cohort
OncoMark have initiated clinical validation of the OncoMasTR test using tumour samples from the TransATAC Tissue Resource.
OncoMark Website Relaunch – New Look and Focus
OncoMark are pleased to announce the launch of their newly designed website www.oncomark.com. The website provides an enhanced user experience to our target audience to access information relating to OncoMark and the OncoMasTR test.
Irish-led research discovers potential new way to treat aggressive type of breast cancer
Study gives new hope of targeted treatment for triple negative breast cancer
Research led by Prof. William Gallagher, Director of BREAST-PREDICT and Chief Scientific Officer of OncoMark, has found a potential new approach to treating one of the most difficult-to-treat forms of breast cancer, which currently has limited treatment options.
OncoMark wins a Champions of EU Research award
OncoMark CEO Des O'Leary was awarded an Ireland's Champions of EU Research award from Enterprise Ireland at an event held in the Royal Hospital Kilmainham yesterday (Wednesday 28th June 2017).
OncoMark Researchers Shed Light on the Discovery and Validation of Master Transcriptional Regulators in Cancer
OncoMark researchers have recently had a review published in the American Association for Cancer Research (AACR) journal, Cancer Research, describing how the reverse engineering of transcriptional networks using gene expression data enables the identification of genes that underpin the development and progression of different cancers.
Prof. William Gallagher Awarded Prestigious Medal for Outstanding Contribution to Irish Cancer Research
Congratulations to Professor William Gallagher, who was the inaugural recipient of the Irish Association of Cancer Research (IACR) Cancer Research Medal at the annual IACR Conference held in Kilkenny on 22nd-24th February 2017.
OncoMark Secures €2.1 Million Investment to Commercialise New Diagnostic Test for Breast Cancer
OncoMasTR test to launch in 2018 and will reduce the number of patients receiving unnecessary chemotherapy
OncoMark wins award at industry event in Brussels!
Mr Des O'Leary, OncoMark's CEO, pitched to an audience of CEOs from more than 400 SMEs from around Europe. The pitch, focusing on our novel OncoMasTR assay for early stage breast cancer, received the award for the best pitch in Health at the SME Instrument Innovators Summit, held in Brussels on 10th-11th October 2016.